An Anti-Inflammatory Sterol Decreases Obesity-Related Inflammation-Induced Insulin Resistance and Metabolic Dysregulation
Figure 4
HE3286-0401 distributions of changes by participant. (a) Day 84 cohort 1 baseline MCP-1 > 40 pmol/L individual subject changes in normalized HbA1c by treatment. (b) Day 84 cohort 1 baseline MCP-1 > 40 pmol/L individual subject changes in homeostatic model assessment of insulin resistance by treatment. (c) Day 84 cohort 2 baseline BMI > 31 kg/m2 individual subject changes in normalized HbA1c by treatment. The circles indicate two outliers detected using Mahalanobis distance. (d) Day 112 cohort 2 baseline BMI > 31 kg/m2 individual subject changes in normalized HbA1c by treatment. (e) Pooled 1,5 anhydroglucitol changes from day 84 cohort 1 and 2 analyses by treatment. Analyses were performed on a subset of patients with available retention samples, predominantly those in cohort 1 with baseline MCP-1 > 40 pmol/L and in cohort 2 with baseline BMI > 31 kg/m2.
